Susan Low

Susan Low has worked in the pharmaceutical industry since 1994, when they began their postdoctoral studies at Harvard University. Susan then moved to the Massachusetts Institute of Technology (MIT) in 1996, where they worked as a Postdoctoral Scientist until 1999. At that time, they joined Syntonix Pharmaceuticals as an Associate Director of Cell Biology and in vivo Pharmacology, where they were a project leader and ran an animal care facility. In 2009, they moved to BIND Biosciences as Head of Biology, where they set up a biology lab and an on-site animal care facility. In 2013, they joined BIND Therapeutics as Senior Director and in 2016, they moved to Lyndra as Vice President of Pharmacology and Toxicology, where they were responsible for preclinical characterization through toxicology evaluation of novel dosage forms. Finally, in 2019, they joined Verseau Therapeutics as Vice President.

Susan Low obtained their PhD in Biology from The University of Edinburgh between 1990 and 1994.